COMMUNIQUÉS West-GlobeNewswire

ZSFab Announces First Clinical Use of 20° Hyperlordotic Cervical Cages in Puerto Rico
26/02/2026
WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Dr. Fernando Villamil recently performed a three-level anterior cervical discectomy and fusion (ACDF) at Ashford Hospital in Puerto Rico using ZSFab’s 20° InterConnect™ [...]
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
26/02/2026
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Clover Health Reports Fourth Quarter & Full Year 2025 Results; Provides Full Year 2026 Guidance
26/02/2026
Business Highlights: Generated full year 2025 Adjusted EBITDA profitability while growing membership by 38% and Insurance revenue by 41% year-over-year Achieved industry-leading 2026 AEP growth of 53% year-over-year [...]
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results
26/02/2026
Record full year 2025 revenue of $236.3 million increased 15% compared to prior year Operating Cash flow improvement of $22 million in full year 2025 Generated $10 million of free cash flow in the fourth quarter, the [...]
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
26/02/2026
Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS II study with higher [...]
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
26/02/2026
Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndrome DNL126 (ETV:SGSH) Phase 1/2 preliminary data [...]
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
26/02/2026
— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE [...]
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/02/2026
PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH- [...]
Keros Therapeutics Appoints Charles Newton to its Board of Directors
26/02/2026
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
DeepHealth Achieves CE Mark for TechLive™ and Enables AWS Marketplace Deployment, Advancing Global Expansion of Multimodality Vendor-Agnostic Remote Scanning Solution
26/02/2026
SOMERVILLE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced that TechLive™, its [...]
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
26/02/2026
2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4 [...]
The Kidney Foundation of Canada highlights need for Canadians to act on kidney health
26/02/2026
Take Action This Kidney Health Month and Ahead of World Kidney Day 2026 MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- As Kidney Health Month gets underway, The Kidney Foundation of Canada is calling on Canadians to take [...]
Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets
26/02/2026
REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a [...]
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/02/2026
– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr [...]
Tarsus to Participate in Upcoming Investor Conferences
26/02/2026
IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: TD Cowen 46 th Annual [...]
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
26/02/2026
Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 million Fourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37% Full Year 2025 Net Income of $52.6 million [...]
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
26/02/2026
CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, [...]
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
26/02/2026
NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today [...]
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
26/02/2026
Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced in 2026 Initial [...]

Pages